After years of taking the opposite tack, the American Heart Association (AHA) is recommending that hormone replacement therapy (HRT) should not be initiated for secondary prevention of cardiovascular disease (CVD) in postmenopausal women.
The recommendation follows results from clinical trials suggesting that no overall cardiovascular benefit results, and a possible early increased risk of CVD events occurs, when women with documented atherosclerosis begin to take HRT (estrogen typically combined with a progestin).
Mitka M. New Advice for Women Patients About Hormone Therapy and the Heart. JAMA. 2001;286(8):907. doi:10.1001/jama.286.8.907-JMN0822-2-1